gemcitabine has been researched along with Angiogenesis, Pathologic in 110 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.91) | 18.2507 |
| 2000's | 38 (34.55) | 29.6817 |
| 2010's | 62 (56.36) | 24.3611 |
| 2020's | 9 (8.18) | 2.80 |
| Authors | Studies |
|---|---|
| Jaidee, R; Jusakul, A; Kongpetch, S; Kukongviriyapan, V; Laphanuwat, P; Prawan, A; Senggunprai, L | 1 |
| Algül, H; Braren, RF; Crone, B; Harder, FN; Heid, I; Jungmann, F; Kaissis, G; Karst, U; Liotta, L; Lohöfer, F; Makowski, MR; Mayer, M; Siveke, JT; Steiger, K; Topping, GJ; Trajkovic-Arsic, M; Weichert, W; Wildgruber, M; Yen, HY | 1 |
| Calvisi, DF; Chen, X; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S; Ribback, S; Serino, G; Wang, J | 1 |
| Cui, M; Dai, M; Gao, J; Guo, J; Kleeff, J; Li, T; Li, Y; Liao, Q; Liu, J; Liu, Q; Lu, Z; Pan, B; Wang, W; Wu, H; Wu, W; Zhang, R; Zhang, T; Zhang, X; Zhao, Y; Zhou, L | 1 |
| Cheng, J; Feldman, R; Fuks, Z; Fuller, J; Kolesnick, R; Owa, T; Tap, W | 1 |
| Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K | 1 |
| Atherton, PJ; Bajorin, D; Ballman, KA; Dreicer, R; Flaig, TW; Hahn, O; Halabi, S; Hoimes, C; Katragadda, S; Misleh, J; Morris, MJ; Mortazavi, A; Picus, J; Plimack, ER; Rosenberg, JE; Small, EJ; Stadler, WM; Sweeney, C; Tagawa, ST; Teply, BA; Vaena, D | 1 |
| Chen, G; Deng, T; Ding, X; Li, J; Wang, Y; Wu, L; Xie, X; Yang, Z; Ye, L; Yu, H; Yu, Z; Zheng, Y; Zhu, Q | 1 |
| Beilhack, A; Caruana, I; Miele, E; Mokhtari, Z; Schlegel, PG; Schneider, T; Schwinn, S; Sirén, AL; Thusek, S; Tiemeyer, N; Wölfl, M | 1 |
| Chang, A; Gao, S; Hao, J; Huang, C; Li, N; Li, Y; Li, Z; Ren, H; Wang, H; Wang, X; Yang, S; Zhao, T | 1 |
| Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO | 1 |
| Che, X; Cheng, X; Du, Z; Huang, X; Li, J; Lin, D; Shao, M; Tan, W; Wang, C; Wu, C; Zhao, Y; Zheng, J | 1 |
| Cao, J; Chen, K; Cheng, L; Duan, W; Jiang, Z; Li, J; Ma, Q; Qian, W; Yan, B; Zhou, C | 1 |
| Bartsch, JW; Bronsert, P; Conrad, C; Hoeppner, J; Kulemann, B; Lopatta, P; Maurer, J; Nyström, A; Oria, VO; Preca, BT; Schilling, O; Schmitz, T | 1 |
| Du, S; Lu, Y; Xiong, H; Xu, C; Yao, J | 1 |
| Hara, M; Hayashi, Y; Imafuji, H; Koide, S; Matsuo, Y; Morimoto, M; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, HJ | 1 |
| Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T | 1 |
| Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
| Huang, L; Kim, WY; Rogers, AB; Schwerbrock, NM; Zhang, Y | 1 |
| Fang, J; Jiang, G; Li, D; Tao, H; Yang, Y; Zhang, J; Zhou, S | 1 |
| Centeno, BA; Chellappan, SP; Lawrence, NJ; Pernazza, D; Pillai, S; Sebti, SM; Singh, S; Treviño, JG; Verma, M; Zhang, D | 1 |
| Cha, H; Cho, WJ; Dung, le TK; Lee, HY; Lee, SJ; Min, YJ; Moon, CH; Park, JW | 1 |
| Aprahamian, M; Bour, G; Giese, NA; Grekova, SP; Lehn, JM; Nicolau, C; Raykov, Z | 1 |
| Saif, MW | 1 |
| Arra, C; Barbieri, A; Bimonte, S; Luciano, A; Palma, G; Rea, D | 1 |
| Gore, AJ; Korc, M; Liu, F; Wilson, JL | 1 |
| Aberson, HL; Duitman, J; Queiroz, KC; Richel, DJ; Shi, K; Spek, CA; van Noesel, CJ; Wilmink, JW | 1 |
| Han, B; Ji, L; Jia, G; Jiang, H; Li, Y; Liu, J; Lv, J; Pan, S; Song, Z; Sun, B; Teng, Y; Wang, Y; Zhou, Y | 1 |
| Abramovitch, R; Corchia, N; Dery, E; Fried, I; Gross, E; Komar-Stossel, C; Meir, K | 1 |
| Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S | 1 |
| Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H | 1 |
| Arumugam, T; Elmetwally, AM; Lin, HY; Mousa, SA; Nazeer, T; Phillips, P; Sudha, T; Yalcin, M | 1 |
| Bruchard, M; Ghiringhelli, F | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Ke, Y; Li, XN; Ruan, J; Yi, SY; Zhao, L | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Awasthi, N; Brekken, RA; Hinz, S; Schwarz, MA; Schwarz, RE | 1 |
| Alrawashdeh, W; Cereser, B; Crnogorac-Jurcevic, T; Demircioglu, F; Elia, G; Ghazaly, E; Hagemann, T; Hodivala-Dilke, KM; Kocher, HM; McDonald, S; Scudamore, CL; Stratford, MR; Wong, PP | 1 |
| Baba, T; Furukawa, K; Li, YY; Matsugo, S; Mukaida, N; Sasaki, S; Song, Y; Tanabe, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Ohashi, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Arora, S; Bhardwaj, A; Carter, JE; Khan, MA; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC | 1 |
| Bai, R; Ding, T; Lan, X; Liu, S; Yin, L; Yu, Y; Zhang, L; Zhao, J | 1 |
| Apte, MV; Biankin, AV; Goldstein, D; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML | 1 |
| Buczkowski, AK; Chung, SW; Kozlowski, P; Kyle, AH; Minchinton, AI; Ng, SS; Owen, DA; Scudamore, CH; Tso, J; Valdez, SM; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Amendt, C; Bruns, CJ; Eichhorn, ME; Ischenko, I; Jauch, KW; Kleespies, A; Mantell, O; Seeliger, H | 1 |
| Mei, K; Tian, L; Wang, L; Wei, Y; Yu, J; Zhang, Z | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Beck, AW; Brekken, RA; Carbon, JG; Dineen, SP; Mamluk, R; Miller, AF; Sullivan, LA; Wong, H | 1 |
| Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J | 1 |
| Finn, RS; Zhu, AX | 1 |
| Chu, Z; Mao, L; Ren, H | 1 |
| Adams, J; Allard, D; Caldwell, ME; Chang, A; Combs, C; Davidson, CJ; Davies, SE; Denicola, G; Dhara, M; Egorin, M; Feig, C; Frese, KK; Goldgraben, MA; Gopinathan, A; Griffiths, J; Grützmann, R; Hingorani, SR; Honess, D; Howat, WJ; Hruban, RH; Huang, P; Iacobuzio-Donahue, C; Ireland-Zecchini, H; Izeradjene, K; Jacobetz, MA; Madhu, B; McGovern, K; McIntyre, D; Olive, KP; Pilarsky, C; Plunkett, W; Reichelt, S; Rückert, F; Tuveson, DA; Wang, L; Whitebread, N; Winter, SP | 1 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Hanahan, D; Olson, P | 1 |
| Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Cui, DD; Huang, XB; Huang, Y; Ji, LL; Liu, TG; Mao, SH; Song, HB; Yi, C | 1 |
| Aggarwal, BB; Inamoto, T; Kamat, AM; Sung, B; Tharakan, ST | 1 |
| Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A | 1 |
| Chen, H; Jiang, H; Kong, R; Krissansen, GW; Pan, S; Sun, B; Sun, X; Wang, S | 1 |
| Awasthi, N; Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 1 |
| Backer, JM; Backer, MV; Buhr, HJ; Hotz, B; Hotz, HG | 1 |
| Bellone, G; Brondino, G; Ciuffreda, L; Cristiano, C; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Hamamoto, Y; Kamimura, M; Takano, N; Yamada, K | 1 |
| Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S | 1 |
| Bi, F; Chen, Y; Cheng, K; Ge, J; Gong, FM; Li, Q; Liu, JY; Peng, XC; Qiu, M; Tan, BX; Wei, M; Wu, Y; Xu, F; Zhao, Y; Zhou, Y | 1 |
| Aggarwal, BB; Park, B; Prasad, S; Sung, B; Yadav, V | 1 |
| Chougule, MB; Jackson, T; Patel, A; Sachdeva, P; Singh, M | 1 |
| Cesta, C; Dantzig, AH; Foster, FS; Francia, G; Hackl, C; Hashimoto, K; Kerbel, RS; Man, S; Shaked, Y; Stewart, J; Sun, J; Uhlik, M; Xu, P; Yin, M | 1 |
| Bookman, MA | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Anant, S; Balakrishnan, A; Chakrabarti, D; Padigaru, M; Periyasamy, G; Ponnurangam, S; Sharma, S; Subramaniam, D; Sugumar, A; Weir, SJ | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Chyczewska, E; Korniluk, M; Mroz, RM; Ossolinska, M; Panek, B | 1 |
| Duan, W; Li, X; Liu, H; Ma, Q; Wu, E; Xu, H | 1 |
| Akhisaroglu, M; Beckhove, P; Buchler, MW; Ge, Y; Grenacher, L; Haefeli, WE; Hohmann, N; Knebel, P; Koch, M; Leowardi, C; Lubenau, H; Mikus, G; Niethammer, AG; Schmitz-Winnenthal, FH; Springer, M; Weitz, J | 1 |
| Beviglia, L; Fischer, MM; Gurney, A; Hoey, T; Hynes, M; Kapoun, AM; Kim, E; Lewicki, J; Simeone, DM; Song, X; Wu, J; Yen, WC; Yeung, VP | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Bruns, CJ; Ellis, LM; Harbison, MT; Hicklin, DJ; Jauch, KW; Portera, C; Radinsky, R; Shrader, M; Solorzano, CC | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Bruns, CJ; Geissler, EK; Guba, M; Hoehn, A; Jauch, KW; Koehl, GE; Schwend, A; Seeliger, H; Steinbauer, M; Yezhelyev, M | 1 |
| Fidler, IJ; Yokoi, K | 1 |
| Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F | 1 |
| Hara, I; Kamidono, S; Kawabata, G; Miyake, H; Muramaki, M | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Ohkawa, S; Tarao, K; Ueno, M | 1 |
| Hedley, DW; Sutton, KL; Wheeler, JJ; Yau, CY | 1 |
| Deng, HX; Kan, B; Li, J; Mei, K; Tian, L; Wei, YQ; Wen, YJ | 1 |
| Ding, ZY; Hu, B; Kan, B; Li, Q; Liu, JY; Luo, Y; Mao, YQ; Niu, T; Su, JM; Tian, L; Wei, YQ; Wen, YJ; Wu, Y; Xie, XJ; Yang, L | 1 |
| Duquette, M; Galardi, E; Lawler, J; Parangi, S; Zhang, X | 1 |
| Barge, A; Bruns, CJ; Friedrich, M; Jauch, KW; Kleespies, A; Köhl, G; Ryan, AJ | 1 |
| Amoh, Y; Bouvet, M; Hoffman, RM; Katsuoka, K; Li, L; Moossa, AR; Tsuji, K | 1 |
| Baker, CH; Caron, A; Fidler, IJ; Gallick, GE; Nesbit, M; Summy, JM; Trevino, JG; Zhang, F | 1 |
| Abbruzzese, JL; Abdelrahim, M; Baker, CH; Safe, S | 1 |
| Ajiki, T; Fujimori, T; Fujita, T; Hirata, K; Hori, H; Horiuchi, H; Kamigaki, T; Kuroda, Y; Mita, Y; Okazaki, T | 1 |
| Aggarwal, BB; Diagaradjane, P; Gelovani, J; Guha, S; Krishnan, S; Kunnumakkara, AB | 1 |
| Henson, R; Meng, F; Patel, T | 1 |
| Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Cao, LM; Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Beinert, T; Binder, D; Fleischhacker, M; Mergenthaler, HG; Oehm, C; Possinger, K; Priem, F; Schweigert, M; Sezer, O; Siebert, G; Stuschke, M; Werner, TG; Ziemer, S | 1 |
| Abbruzzese, JL; Bruns, CJ; Davis, DW; Evans, DB; Harbison, MT; Hicklin, DJ; McConkey, DJ; Portera, CA; Radinsky, R; Tsan, R | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
4 review(s) available for gemcitabine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; Gemcitabine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammasomes; Interleukin-17; Interleukin-1beta; Mice; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; NLR Family, Pyrin Domain-Containing 3 Protein; Tyrosine | 2014 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment.
Topics: Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Neuronal Plasticity; Paracrine Communication; Tumor Microenvironment | 2012 |
5 trial(s) available for gemcitabine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Sunitinib | 2020 |
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Neovascularization, Pathologic; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms | 2021 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Swine; Venous Thromboembolism | 2008 |
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cancer Vaccines; Clinical Trials, Phase I as Topic; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Placebos; Randomized Controlled Trials as Topic; Salmonella typhi; Vaccines, DNA; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
101 other study(ies) available for gemcitabine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.
Topics: Animals; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Gemcitabine; Humans; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Pancreatic Neoplasms; Tomography; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2022 |
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Topics: Adaptor Proteins, Signal Transducing; Amyloid Precursor Protein Secretases; Animals; Benzazepines; Bile Duct Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 13; Mice, Nude; Microvessels; Neovascularization, Pathologic; Receptor, Notch1; Reproducibility of Results; RNA, Messenger; Signal Transduction; Transcriptome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphangiogenesis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Survival Rate; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Deoxycytidine; Endothelial Cells; Gemcitabine; Male; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sarcoma; Soft Tissue Neoplasms; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Cytoskeleton; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Amplification; Gene Expression; Humans; Medulloblastoma; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2021 |
Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CCL5; Chemokine CXCL1; Chemotaxis, Leukocyte; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-12 Subunit p35; Interleukin-8; Interleukins; Macrophages; Mice, SCID; Microvessels; Minor Histocompatibility Antigens; Monocytes; Neovascularization, Pathologic; Pancreatic Neoplasms; Paracrine Communication; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2018 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Homeodomain Proteins; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mutation; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Trans-Activators; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2018 |
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Topics: ADAM Proteins; Adenocarcinoma; Animals; Basement Membrane; Biocatalysis; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Lymphangiogenesis; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Signal Transduction | 2019 |
Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Deoxycytidine; Gemcitabine; Hep G2 Cells; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Liver Neoplasms; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Transplantation, Heterologous | 2019 |
Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Neovascularization, Pathologic; Pancreatic Neoplasms | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; NF-kappa B; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; rho GTP-Binding Proteins; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Sulfasalazine; Tomography, X-Ray Computed | 2013 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Genetic Therapy; Humans; Lung Neoplasms; Mice; Nanoparticles; Neovascularization, Pathologic; RNA, Small Interfering; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Genes, Reporter; Lung Neoplasms; Mice; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tumor Burden | 2013 |
Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzophenones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Mice, Mutant Strains; Microtubules; Neoplasms; Neovascularization, Pathologic; Tubulin; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2014 |
Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorescent Antibody Technique; Gemcitabine; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inositol Phosphates; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Oxygen; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms | 2013 |
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Signal Transduction; Transcription, Genetic; Xenograft Model Antitumor Assays | 2014 |
Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Receptor, PAR-1; Signal Transduction; Stromal Cells; Tumor Cells, Cultured | 2014 |
Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microvessels; Naphthoquinones; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Administration Schedule; Drug Combinations; Drug Synergism; Gemcitabine; Gene Amplification; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Mice, Inbred NOD; Mice, SCID; N-Myc Proto-Oncogene Protein; Neovascularization, Pathologic; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Platelet Endothelial Cell Adhesion Molecule-1; Sulfasalazine; Treatment Outcome; Tretinoin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Immunohistochemistry; Losartan; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Deoxycytidine; Enzyme Inhibitors; Female; Fibrinolytic Agents; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2014 |
Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts.
Topics: AC133 Antigen; Angiogenesis Inhibitors; Animals; Antigens, CD; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Cells; Gemcitabine; Glycoproteins; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Peptides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Indoles; Neoplasms, Experimental; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2015 |
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Reactive Oxygen Species; Treatment Outcome; Up-Regulation | 2015 |
[A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy].
Topics: Antimetabolites, Antineoplastic; Arteries; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Topics: Animals; Apoptosis; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Thalidomide; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Chromones; Deoxycytidine; Gemcitabine; Humans; Morpholines; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Hepatocyte Growth Factor; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2016 |
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones | 2016 |
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; Mice, SCID; Microvessels; Necrosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Perfusion; Xenograft Model Antitumor Assays | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Chemokine CXCL10; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Deoxycytidine; Gemcitabine; Genetic Therapy; Mice; Models, Animal; Neovascularization, Pathologic; Plasmids; Transfection | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neovascularization, Pathologic; Xenograft Model Antitumor Assays | 2009 |
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Stromal Cells; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Cancer. Breaching the cancer fortress.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Fibroblasts; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Stromal Cells | 2009 |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Deoxycytidine; Drug Synergism; Gemcitabine; Losartan; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Growth Processes; Deoxycytidine; Female; Gemcitabine; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; DNA Primers; Drug Synergism; Gemcitabine; Humans; Models, Biological; Neovascularization, Pathologic; Urinary Bladder Neoplasms | 2010 |
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2010 |
Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; DNA; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transcription Factor RelA | 2010 |
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Immunoenzyme Techniques; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Endothelium, Vascular; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shiga Toxins; Signal Transduction; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pilot Projects; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2010 |
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasms, Multiple Primary; Neovascularization, Pathologic; Tomography, X-Ray Computed | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
Different combination schedules of gemcitabine with endostar affect antitumor efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Deoxycytidine; Drug Administration Schedule; Endostatins; Gemcitabine; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Recombinant Proteins; Vascular Endothelial Growth Factor A | 2012 |
Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Triterpenes; Xenograft Model Antitumor Assays | 2011 |
Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antitussive Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Noscapine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Vessels; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oncogenes; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
sVEGF R1 and Tie-2 levels during chemotherapy of lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pulmonary Disease, Chronic Obstructive; Receptor, TIE-2; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Anti-Idiotypic; Calcium-Binding Proteins; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cells; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Cell Death; Cell Division; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Sirolimus; Transplantation, Heterologous | 2004 |
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine | 2004 |
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cyclohexanes; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Pancreatic Neoplasms; Polysaccharides; Prognosis; Pyridines; Survival Analysis; Survival Rate; Tegafur; Ultrasonography | 2005 |
Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenograf
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2005 |
[Antitumor effects of interferon-gamma-inducible protein 10 combined with gemcitabine].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Chemokine CXCL10; Chemokines, CXC; Deoxycytidine; Drug Synergism; Escherichia coli; Female; Gemcitabine; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microcirculation; Neovascularization, Pathologic; Plasmids; Transfection | 2005 |
Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endostatins; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Recombinant Proteins; Xenograft Model Antitumor Assays | 2005 |
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, SCID; Microcirculation; Microscopy, Fluorescence; Molecular Sequence Data; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein Structure, Tertiary; Recombinant Proteins; Thrombospondin 1; Time Factors | 2005 |
Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Coloring Agents; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunohistochemistry; Liver; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Organophosphorus Compounds; Pancreatic Neoplasms; Tetrazolium Salts; Thiazoles; Tubulin; Umbilical Veins | 2005 |
Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Green Fluorescent Proteins; Humans; Immunohistochemistry; Intermediate Filament Proteins; Mice; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Transfection; Transplantation, Heterologous | 2006 |
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases | 2006 |
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Deoxycytidine; Electrophoretic Mobility Shift Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Laser Scanning Cytometry; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; ortho-Aminobenzoates; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp Transcription Factors; Sp1 Transcription Factor; Sp3 Transcription Factor; Sp4 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Cell Proliferation; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells.
Topics: Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Movement; Cells, Cultured; Deoxycytidine; Diethylnitrosamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelial Cells; Gemcitabine; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Microcirculation; Neovascularization, Pathologic; NF-kappa B; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface; Time Factors; Transfection; Vascular Endothelial Growth Factor A | 2007 |
Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cancer Vaccines; Cell Proliferation; Chickens; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 1; Gemcitabine; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Recombinant Proteins; Survival Rate | 2007 |
Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cancer Vaccines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Receptor, Fibroblast Growth Factor, Type 1; Recombinant Proteins | 2007 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphokines; Male; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Oxidative Stress; Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vindesine | 1999 |
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cetuximab; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |